REFERENCES
- Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl 1999; 56: 18–24, [PUBMED], [INFOTRIEVE]
- Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 84(2A)20–24, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Walan A, Wahlqvist P. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol 1999; 31(Suppl 1)S79–88, [PUBMED], [INFOTRIEVE]
- Rahme E, Joseph L, Kong SX, Watson DJ, LeLorier J. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Br J Clin Pharmacol 2001; 52(2)185–192, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Vane JR, Warner TD. Nomenclature for COX-2 inhibitors. Lancet 2000; 356(9239)1373–1374, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2000; 99(21)13926–13931, [CROSSREF]
- Simmons DL. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 2003; 110(5–6)265–268, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wolfe MM., Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340(24)1888–1899, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stichtenoth DO, Frolich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer?. Drugs 2003; 63(1)33–45, [PUBMED], [INFOTRIEVE]
- Jackson LM, Hawkey CJ. COX-2 selective nonsteroidal anti-Inflammatory drugs: do they really offer any advantages?. Drugs 2000; 59(6)1207–1216, [PUBMED], [INFOTRIEVE]
- Evensen S, Spigset O, Slordal L. [COX-2 inhibitors—one step forward and two steps back]. Tidsskr Nor Laegeforen 2005; 125(7)875–878, [PUBMED], [INFOTRIEVE]
- Bort R, Ponsoda X, Carrasco E, Gomez-Lechon MJ, Castell JV. Metabolism of aceclofenac in humans. Drug Metab Dispos 1996; 24(8)834–841, [PUBMED], [INFOTRIEVE]
- Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74(3)222–235, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hutt AJ, Caldwell J, Smith RL. The metabolism of aspirin in man: a population study. Xenobiotica 1986; 16(3)239–249, [PUBMED], [INFOTRIEVE]
- Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001; 61(9)3566–3569, [PUBMED], [INFOTRIEVE]
- MacDonald CJ, Ciolino HP, Yeh GC. The drug salicylamide is an antagonist of the aryl hydrocarbon receptor that inhibits signal transduction induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 2004; 64(1)429–434, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chen XP, Tan ZR, Huang SL, Huang Z, Ou-Yang DS, Zhou HH. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther 2003; 73(3)264–271, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004; 5(3)211–224, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Martinez C, Garcia-Martin E, Ladero JM, Sastre J, Garcia-Gamito F, Diaz-Rubio M, Agundez JA. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis 2001; 22(8)1323–1326, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS. A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol Hepatol 2004; 2(8)704–712, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH, Jr, Piergies A, Karim A. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab Dispos 2000; 28(3)308–314, [PUBMED], [INFOTRIEVE]
- Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002; 54(4)423–429, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 2000; 293(2)453–459, [PUBMED], [INFOTRIEVE]
- Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11(3)223–235, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kirchheiner J, Tsahuridu M, Jabrane W, Roots I, Brockmoller J. The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendations. Personalized Med 2004; 1(1)63–84, [CROSSREF]
- Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77(1)1–16, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brenner SS, Herrlinger C, Dilger K, Murdter TE., Hofmann U, Marx C, Klotz U. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003; 42(3)283–292, [PUBMED], [INFOTRIEVE]
- Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13(8)473–480, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao Y. Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. Drug Metabol Drug Interact 2003; 19(4)287–295, [PUBMED], [INFOTRIEVE]
- Malhi H, Atac B, Daly AK, Gupta S. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgrad Med J 2004; 80(940)107–109, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M, Agundez JA. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 2004; 141(2)205–208, [PUBMED], [INFOTRIEVE], [CROSSREF]
- King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001; 61(1)49–53, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Stierlin H, Faigle JW, Sallmann A, Kung W, Richter WJ, Kriemler HP, Alt KO, Winkler T. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 1979; 9(10)601–610, [PUBMED], [INFOTRIEVE]
- Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 1999; 58(5)787–796, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tang W. The metabolism of diclofenac—enzymology and toxicology perspectives. Curr Drug Metab 2003; 4(4)319–329, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC, Baillie TA. Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. J Pharmacol Exp Ther 2002; 303(3)969–978, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Morin S, Loriot MA, Poirier JM, Tenneze L, Beaune PH, Funck-Brentano C, Jaillon P, Becquemont L. Is diclofenac a valuable CYP2C9 probe in humans?. Eur J Clin Pharmacol 2001; 56(11)793–797, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dorado P, Berecz R, Caceres MC, Llerena A. Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 789(2)437–442, [PUBMED], [INFOTRIEVE]
- Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003; 55(1)51–61, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjoqvist F, Dahl ML. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 2001; 57(10)729–735, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Aithal GP, Day CP, Leathart JB, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10(6)511–518, [PUBMED], [INFOTRIEVE], [CROSSREF]
- van Dijk KN, Plat AW, van Dijk AA, Piersma-Wichers M, de Vries-Bots AM, Slomp J, de Jong-van den Berg LT, Brouwers JR. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype. Thromb Haemost 2004; 91(1)95–101, [PUBMED], [INFOTRIEVE]
- Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40(4)263–281, [PUBMED], [INFOTRIEVE]
- Agundez JA, Martinez C, Benitez J. Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995; 25(4)417–427, [PUBMED], [INFOTRIEVE]
- Agundez JA, Carrillo JA, Martinez C, Benitez J. Aminopyrine metabolism in man: the acetylation of aminoantipyrine cosegregates with acetylation of caffeine. Ther Drug Monit 1995; 17(1)1–5, [PUBMED], [INFOTRIEVE]
- Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995; 28(3)216–234, [PUBMED], [INFOTRIEVE]
- Bacracheva N, Tyutyulkova N, Drenska A, Gorantcheva J, Schinzel S, Scholl T, Stoinov A, Tchakarski I, Tentcheva J, Viahov V. Effect of cimetidine on the pharmacokinetics of the metabolites of metamizol. Int J Clin Pharmacol Ther 1997; 35(7)275–281, [PUBMED], [INFOTRIEVE]
- Agundez JA, Luengo A, Benitez J. Caffeine demethylase activity in human and Dark Agouti rat liver microsomes. Comparison with aminopyrine N-demethylase activity. Drug Metab Dispose 1992; 20(3)343–349
- Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28(2)100–114, [PUBMED], [INFOTRIEVE]
- Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56(2)243–251, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hutzler JM, Kolwankar D, Hummel MA, Tracy TS. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metab Dispos, 2002; 30(11)1194–1200
- Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 2003; 58(12)791–794, [PUBMED], [INFOTRIEVE]
- Davies NM. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998; 34(2)101–154
- Adams SS, Bresloff P, Mason CG. Pharmacological differences between the optical isomers of ibuprofen: evidence for metabolic inversion of the (−)-isomer. J Pharm Pharmacol 1976; 28(3)256–257, [PUBMED], [INFOTRIEVE]
- Geisslinger G, Stock KP, Bach GL, Loew D, Brunel K. Pharmacological differences between R(−)- and S(+)-ibuprofen. Agents Actions 1989; 27(3–4)455–457, [PUBMED], [INFOTRIEVE]
- Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 1992; 42(3)237–256, [PUBMED], [INFOTRIEVE]
- Villanueva M, Heckenberger R, Strobach H, Palmer M, Schror K. Equipotent inhibition by R(−)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. Br J Clin Pharmacol 1993; 35(3)235–242, [PUBMED], [INFOTRIEVE]
- Geisslinger G, Stock KP, Loew D, Bach GL, Brune K. Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35(6)603–607, [PUBMED], [INFOTRIEVE]
- Kaiser DG, Vangiessen GJ, Reischer RJ, Wechter WJ. Isomeric inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci 1976; 65(2)269–273, [PUBMED], [INFOTRIEVE]
- Lee EJ, Williams K, Day R, Graham G, Champion D. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 1985; 19(5)669–674, [PUBMED], [INFOTRIEVE]
- Day RO, Williams KM, Graham GG, Lee EJ, Knihinicki RD, Champion GD. Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clin Pharmacol Ther 1988; 43(5)480–487, [PUBMED], [INFOTRIEVE]
- Avgerinos A, Hutt AJ. Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. Chirality 1990; 2(4)249–256, [PUBMED], [INFOTRIEVE]
- Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997; 54(1)33–41, [PUBMED], [INFOTRIEVE]
- Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002; 72(1)62–75, [PUBMED], [INFOTRIEVE]
- Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 2004; 76(2)119–127, [PUBMED], [INFOTRIEVE]
- Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, Agundez JA. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 2005; 59(1)62–69, [PUBMED], [INFOTRIEVE]
- Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes. Drug Metab Dispos 1998; 26(3)261–266, [PUBMED], [INFOTRIEVE]
- Duggan DE, Hogans AF, Kwan KC, McMahon FG. The metabolism of indomethacin in man. J Pharmacol Exp Ther, 1972; 181(3)563–575
- Zarza J. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9. Thromb Haemost 2003; 90(1)161–162, [PUBMED], [INFOTRIEVE]
- Pullar T, Capell HA. Interaction of indomethacin and warfarin. Br Med J (Clin Res Ed) 1982; 284(6310)198
- Chan TY, Lui SF, Chung SY, Luk S, Critchley JA. Adverse interaction between warfarin and indomethacin. Drug Saf 1994; 10(3)267–269, [PUBMED], [INFOTRIEVE]
- Vesell ES, Passananti GT, Johnson AO. Failure of indomethacin and warfarin to interact in normal human volunteers. J Clin Pharmacol 1975; 15(7)486–495, [PUBMED], [INFOTRIEVE]
- Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet 1998; 34(6)421–428, [PUBMED], [INFOTRIEVE]
- Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D. Pharmacokinetics of lornoxicam in man. Postgrad Med J, 1990; 66(Suppl 4)S22–27
- Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H. Role of cyp2c9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005; 33(6)749–753, [PUBMED], [INFOTRIEVE]
- Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol. 2005; 59(1)14–17, [PUBMED], [INFOTRIEVE]
- Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol, 1996; 49(4)305–308
- Iida I, Miyata A, Arai M, Hirota M, Akimoto M, Higuchi S, Kobayashi K, Chiba K. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5′-hydroxylation. Drug Metab Dispos. 2004; 32(1)7–9, [PUBMED], [INFOTRIEVE]
- Kohl C, Steinkellner M. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos 2000; 28(2)161–168, [PUBMED], [INFOTRIEVE]
- Masche UP, Rentsch KM, von Felten A, Meier PJ, Fattinger KE. No clinically relevant effect of lornoxicam intake on acenocoumarol pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol. 1999; 54(11)865–868, [PUBMED], [INFOTRIEVE]
- Masche UP, Rentsch KM, von Felten A, Meier PJ, Fattinger KE. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics. Eur J Clin Pharmacol. 1999; 54(11)857–864, [PUBMED], [INFOTRIEVE]
- Ravic M, Johnston A, Turner P, Ferber HP. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol. 1990; 9(6)413–414, [PUBMED], [INFOTRIEVE]
- Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica. 1998; 28(1)1–13, [PUBMED], [INFOTRIEVE]
- Ludwig E, Schmid J, Beschke K, Ebner T. Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5′-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999; 290(1)1–8, [PUBMED], [INFOTRIEVE]
- Xu HY, Zhong DF, Zhao LM, Zhang YF, Zhang BJ. [Pharmacokinetics of meloxicam in healthy Chinese volunteers]. Yao Xue Xue Bao 2001; 36(1)71–73, [PUBMED], [INFOTRIEVE]
- Jaggi R, Addison RS, King AR, Suthers BD, Dickinson RG. Conjugation of desmethylnaproxen in the rat–a novel acyl glucuronide-sulfate diconjugate as a major biliary metabolite. Drug Metab Dispos, 2002; 30(2)161–166
- Miners JO, Coulter S, Tukey RH, Veronese ME, Birkett DJ. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996; 51(8)1003–1008, [PUBMED], [INFOTRIEVE]
- Karim A, Laurent A, Slater ME, Kuss ME, Qian J, Crosby-Sessoms SL, Hubbard RC. A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects. J Clin Pharmacol 2001; 41(10)1111–1119, [PUBMED], [INFOTRIEVE]
- Ibrahim A, Park S, Feldman J, Karim A, Kharasch ED. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology 2002; 96(1)88–95, [PUBMED], [INFOTRIEVE]
- Ibrahim A, Karim A, Feldman J, Kharasch E. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg, 2002; 95(3)667–673
- Ibrahim AE, Feldman J, Karim A, Kharasch ED. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology, 2003; 98(4)853–861
- Richardson CJ, Blocka KL, Ross SG, Verbeeck RK. Piroxicam and 5′-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur J Clin Pharmacol 1987; 32(1)89–91, [PUBMED], [INFOTRIEVE]
- Zhao J, Leemann T, Dayer P. In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci 1992; 51(8)575–581, [PUBMED], [INFOTRIEVE]
- Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile 359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics, 2000; 10(2)95–104
- Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9; effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30(4)385–390, [PUBMED], [INFOTRIEVE]
- Dell D, Joly R, Meister W, Arnold W, Partos C, Guldimann B. Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its major metabolite, in human urine. J Chromatogr 1984; 317: 483–492, [PUBMED], [INFOTRIEVE]
- Olkkola KT, Brunetto AV, Mattila MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 1994; 26(2)107–120, [PUBMED], [INFOTRIEVE]
- Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004; 76(1)18–26, [PUBMED], [INFOTRIEVE]
- Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994; 26(1)16–43, [PUBMED], [INFOTRIEVE]
- Totah RA, Rettie AE. Cytochrome P450 2C8; substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77(5)341–352, [PUBMED], [INFOTRIEVE]
- Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12(3)251–263, [PUBMED], [INFOTRIEVE]